Citations

Showing 10 of 108083 citations.

Early-Onset Parkinson’s Disease: Creating the Right Environment for a Genetic Disorder
Kolicheski, Ana , Turcano, Pierpaolo , Tamvaka, Nicole , McLean, Pamela J. , Springer, Wolfdieter , Savica, Rodolfo , Ross, Owen A. , Ross, Owen A , Springer, Wolfdieter , McLean, Pamela J

Mayo Clinic

Journal of Parkinson's Disease | December 6, 2022 | Volume: 12 | Issue: 8 | Pages: 2353-2367

10.3233/jpd-223380 | PMID 36502340 Get It

Parkinson’s disease (PD) by its common understanding is a late-onset sporadic movement disorder. However, there is a need to recognize not only the fact that PD pathogenesis expands beyond (or perhaps to) the brain but also that many early-onset patients develop motor signs before the age of 50 years. Indeed, studies have shown that it is likely the protein aggregation observed in the brains of patients with PD precedes the motor symptoms by perhaps a decade. Studies on early-onset forms of PD have shown it to be a heterogeneous disease with multiple genetic and environmental factors determining risk of different forms of disease. Genetic and neuropathological evidence suggests that there are α-synuclein centric forms (e.g., SNCA genomic triplication), and forms that are driven by a breakdown in mitochondrial function and specifically in the process of mitophagy and clearance of damaged mitochondria (e.g., PARKIN and PINK1 recessive loss-of-function mutations). Aligning genetic forms with recognized environmental influences will help better define patients, aid prognosis, and hopefully lead to more accurately targeted clinical trial design. Work is now needed to understand the cross-talk between these two pathomechanisms and determine a sense of independence, it is noted that autopsies studies for both have shown the presence or absence of α-synuclein aggregation. The integration of genetic and environmental data is critical to understand the etiology of early-onset forms of PD and determine how the different pathomechanisms crosstalk.
The Combination of TIM3-Based Checkpoint Blockade and Oncolytic Virotherapy Regresses Established Solid Tumors
Gowan, Cody C., Bartee, Mee Y., Flores, Erica , Aksoy, Bülent Arman , Templeton, Conor W. , Baillie, Kati, Happe, Myroslawa, Bartee, Eric , Happe, Myra

Mayo Clinic

Journal of Immunotherapy | December 6, 2022 | Volume: 46 | Issue: 1 | Pages: 1-4

10.1097/cji.0000000000000444 | PMID 36472581 Get It

T-cell immunoglobulin and mucin domain 3 (TIM3) is emerging as a potential target for antibody-based checkpoint blockade. However, the efficacy of TIM3 blockade in combination with other treatment modalities, has not been extensively studied. In the current work we combined TIM3 blockade with myxoma virus-based oncolytic virotherapy (OV). Our results demonstrate that myxoma virus’s ability to initiate an immense antitumor immune response complements the ability of TIM3 blockade to shift the tumor microenvironment to a more proinflammatory state. As a result, the combination of TIM3 blockade and OV is able to completely eradicate established disease, while neither monotherapy is effective. These data represent the first demonstration that OV can enhance the efficacy of TIM3 blockade and suggest that this treatment may need to be incorporated into more aggressive, combinatorial regimens in order to fulfill its potential as an immunotherapeutic.
Improved Glycemia with Hybrid Closed-Loop Versus Continuous Subcutaneous Insulin Infusion Therapy: Results from a Randomized Controlled Trial
Grunberger, George , Weinstock, Ruth S. , Hirsch, Irl B. , DiMeglio, Linda A. , Philis‐Tsimikas, Athena , Kipnes, Mark, Liljenquist, David R., Brazg, Ronald, Kudva, Yogish C. , Buckingham, Bruce A. , Carlson, Anders L. , Criego, Amy , Christiansen, Mark P., Kaiserman, Kevin B. , Forlenza, Gregory P. , Bode, Bruce W. , Slover, Robert H., Keiter, Ashleigh , Ling, Chenxiao , Marinos, Briggitte, Cordero, Toni L. , Shin, John , Lee, Scott W., Rhinehart, Andrew S., Group, for the Adult and Pediatric MiniMed™ HCL Outcomes 6-month RCT: HCL versus CSII Control Study, Downs, Ashleigh, Lange, Samantha , Jost, Emily , KARAMI, ANGELA J., Hamill, Donna, Simha, Vinaya , Desjardins, Donna, Spitzer, Shelly McCrady, Reid, Corey, Kaur, Ravinderjeet, Malone, Halvorson, Mary, Ekhlaspour, Laya , Weir, Christine, Casaubon, Luis, Ang, Lynn , Plunkett, Cindy, Recklein, Carol, Clifton, Mary Jane, Weinstock, Ruth S , Hirsch, Irl B , Kudva, Yogish C. , McGill, Janet B. , Forlenza, Gregory P , Cordero, Toni L , Vigersky, Robert A , Philis-Tsimikas, Athena , Buckingham, Bruce , DiMeglio, Linda , Garg, Satish K. , Lawson, Margaret L. , Pop‐Busui, Rodica , Griffin, Kurt , Vigersky, Robert A. , Group, for the Adult and Pediatric MiniMed™ HCL Outcomes 6-month RCT: HCL versus CSII Control Study, Kaur, Ravinder Jeet , Malone, Stout, Kara Mizokami , Plunkett, Cindy, Williams, Brittany

Mayo Clinic

Diabetes Technology & Therapeutics | December 6, 2022 | Volume: 25 | Issue: 1 | Pages: 1-12

10.1089/dia.2022.0421 | PMID 36472543 Get It

The role of CAR-T cell therapy as second line in diffuse large B-cell lymphoma
Albanyan, Omar , Chávez, Julio C. , Chavez, Julio C , Muñoz, Javier

Mayo Clinic

Therapeutic Advances in Hematology | December 6, 2022 | Volume: 13 | Issue: No issue available | Pages: No page available

10.1177/20406207221141511 | PMID 36505886 Get It

For approximately three decades, autologous hematopoietic cell transplantation (auto-HCT) has been the standard of care for patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) after frontline therapy. This approach is limited due to the intensity of chemotherapy and the proportion of patients who relapse after auto-HCT. Since the approval of anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy and novel agents, the treatment paradigm for DLBCL has changed remarkably. Anti-CD19 CAR-T therapy was first approved for relapsed DLBCL after two or more previous lines of therapy with long-lasting responses, with over 50% of patients still alive at 5-year follow-up. Here, we discuss recent randomized phase 3 clinical trials using axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel in the second-line therapy setting compared with the standard of care in transplant-eligible patients who have DLBCL R/R within 12 months of completing chemo-immunotherapy, potentially changing the treatment algorithm for DLBCL.
Cross-Generational Impact of Innate Immune Memory Following Pregnancy Complications
Lodge‐Tulloch, Nakeisha A., Toews, Alexa J., Atallah, Aline , Cotechini, Tiziana , Graham, Charles H. , Graham, Charles H , Girard, Sylvie

Mayo Clinic

Cells | December 6, 2022 | Volume: 11 | Issue: 23 | Pages: 3935

10.3390/cells11233935 | PMID 36497193 Get It

Pregnancy complications can have long-term negative effects on the health of the affected mothers and their children. In this review, we highlight the underlying inflammatory etiologies of common pregnancy complications and discuss how aberrant inflammation may lead to the acquisition of innate immune memory. The latter can be described as a functional epigenetic reprogramming of innate immune cells following an initial exposure to an inflammatory stimulus, ultimately resulting in an altered response following re-exposure to a similar inflammatory stimulus. We propose that aberrant maternal inflammation associated with complications of pregnancy increases the cross-generational risk of developing noncommunicable diseases (i.e., pregnancy complications, cardiovascular disease, and metabolic disease) through a process mediated by innate immune memory. Elucidating a role for innate immune memory in the cross-generational health consequences of pregnancy complications may lead to the development of novel strategies aimed at reducing the long-term risk of disease.
Effect of Esophagogastroduodenoscopy Volume and Gastric/Esophageal Pathology on the Rate of Lymphocytic Duodenosis Reporting in Children and Adolescents
Devara, Janaki , Manini, Mhd Louai , Absah, Imad , Murray, Joseph A.

Mayo Clinic

Avicenna Journal of Medicine | December 6, 2022 | Volume: 12 | Issue: 04 | Pages: 169-173

10.1055/s-0042-1755388 | PMID 36570431 Get It

Abstract Background It is not clear if the increase in the number of esophagogastroduodenoscopies (EGDs) performed has any significant effect on the rate of lymphocytic duodenosis (LD) reporting in children and adolescents and whether it correlates with abnormal gastric and/or esophageal pathology.” Methods We performed a single-center retrospective study using the Mayo Clinic electronic health record and pathology database. We reviewed all EGD procedures performed in children and adolescents (<18 years) between January 1, 2000, and December 31, 2018, and identified two groups, the LD group and matched age and sex control group (normal duodenal biopsies). We evaluated the correlation of LD rate with the yearly number of EGDs performed and the presence of abnormal gastric and/or esophageal pathology. Results Of 11,870 EGDs performed, we identified 338 (3%) individuals with LD and 390 (3%) randomly selected controls, with a mean (SD) age of 9.6 (5.3) and 11.7 (5.0) years, respectively. Based on logistic regression analysis, abnormal gastric histology was associated with the presence of LD when compared with controls (odds ratio, 2.85; 95% CI, 2.05–3.97; P < 0.001). The rate of LD-positive biopsies per year was highly correlated with the number of EGDs performed (ρ = 0.931; 95% CI, 0.826–0.974; P < 0.001). Conclusion The rate of LD reporting is correlated with the number of EGDs performed and is more likely seen in children and adolescents with abnormal gastric histology.
Development and Examination of a Trainee-Led ECHO Autism Network for Rural Healthcare Providers
Cardon, Garrett , Dahl, Ethan , Diaków, Diana M. , Neumann, Alyssa A. , Mallone, Kalley, Permar, Haley, Benallie, Kandice J. , Haverkamp, Cassity R. , Lindsey, Rebecca A., Romero, Sebastian , Sherman, Whitney M., Hardesty, Canyon, Carbone, Paul S. , Gabrielsen, Terisa P. , Clark, Taylor

Mayo Clinic

Journal of Educational and Psychological Consultation | December 5, 2022 | Volume: 33 | Issue: 4 | Pages: 393-420

10.1080/10474412.2022.2151013 Get It

Case presentation and panel discussion: Transitions in care
Katz, Jennifer , Mercer, David F. , Schüetz, Philipp , Mundi, Manpreet S. , Pimiento, José M. , Morrison, Chet A. , Patel, Jayshil J. , Pimiento, Jose M , Morrison, Chet A , Patel, Jayshil J , Mundi, Manpreet S , Mechanick, Jeffrey I.

Mayo Clinic

Journal of Parenteral and Enteral Nutrition | December 5, 2022 | Volume: 47 | Issue: S1 | Pages: No page available

10.1002/jpen.2438 | PMID 36470242 Get It

AbstractThere is evidence that significant quality problems arise as patients transitions in care from one setting to another. Attention to nutrition during transitions of care is important to avoid complication. During the American Society for Parenteral and Enteral Nutrition 2022 preconference course, nutrition during transition of care from pediatric to adult care, from the intensive care unit to the hospital floors and from the hospital to home was addressed.
S131 Secondary Amyloidosis in Inflammatory Bowel Disease Patients: Findings From Three Tertiary Medical Centers
Gill, Vikram, Boddu, Sayi P. , Abujbarah, Sami , Mathis, Kellie L. , Brady, Justin, Boddu, Sayi , Brady, Justin T.

Mayo Clinic

American Journal of Gastroenterology | December 5, 2022 | Volume: 117 | Issue: 12S | Pages: S33-S34

10.14309/01.ajg.0000898032.49194.8a Get It